Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968027 | 0.86 | GABRA1 (0.48) | ALDH1A1GABRA1GABRB2GPR84OPRM1 | |
| SCHEMBL6442439 | 0.86 | GABRA1 (0.48) | GABRA1GABRB2GPR84ACHETAAR1 | |
| SCHEMBL16962399 | 0.84 | NOS2 (0.43) | GABRA1GABRB2NOS3NOS1NOS2 | |
| SCHEMBL5739348 | 0.84 | NOS3 (0.43) | ALDH1A1GABRA1GABRB2NOS3NOS1 | |
| Phenol SCHEMBL28225282 | 0.80 | GABRA1 (0.42) | GABRA1GABRB2OPRM1ACHETAAR1 | |
| SCHEMBL5164582 | 0.78 | GABRA1 (0.42) | GABRA1GABRB2GPR84OPRM1ACHE | |
| SCHEMBL25146577 | 0.77 | AKR1C2 (0.48) | ALDH1A1GABRA1GABRB2GPR84TAAR1 | |
| SCHEMBL5166193 | 0.77 | GABRA1 (0.41) | GABRA1GABRB2GPR84OPRM1PTGS2 | |
| SCHEMBL30899188 | 0.77 | ALDH1A1 (0.60) | ALDH1A1HCAR1ACHEPTGS2ESR1 | |
| SCHEMBL29215628 | 0.77 | ALDH1A1 (0.60) | ALDH1A1HCAR1ACHEPTGS2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9434761-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20140336106-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| CN-101817713-B | Preparation method of 2, 2'-biphenyl diphenol and derivatives thereof | BEIJING OKEANOS TECHNOLOGY CO LTD | 2013-06-12 | — | — | CN | disclosed |
| CN-101817713-A | Preparation method of 2, 2'-biphenyl diphenol and derivatives thereof | BEIJING OKEANOS TECHNOLOGY CO LTD | 2010-09-01 | — | — | CN | disclosed |
| US-7514520-B2 | Process for producing phosphonitrilic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20080091050-A1 | Process For Producing Phosphonitrilic Acid Ester | ASAHI KASEI CHEMICAL CORPORATION (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070129578-A1 | Method for the production of 2,2'-dihydroxybiphenyls | BASF AKTIENGESELLSCHAFT (DE) | 2007-06-07 | — | — | US | disclosed |
| EP-1633691-B1 | METHOD FOR PRODUCING 2,2'-DIHYDROXY-BIPHENYLS | BASF AG (DE) | 2007-04-11 | — | — | EP | disclosed |
| US-20070060739-A1 | Process for producing phosphonitrilic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1682473-A1 | METHOD FOR THE PRODUCTION OF 2,2'-DIHYDROXYBIPHENYLS | BASF Aktiengesellschaft (DE) | 2006-07-26 | — | — | EP | disclosed |
| CN-1802339-A | Method for producing 2,2'-dihydroxy-biphenyls | BASF AG (DE) | 2006-07-12 | — | — | CN | disclosed |
| CN-1798753-A | Process for producing phosphonitrilic acid ester | ASAHI CHEMICAL CORP (JP) | 2006-07-05 | — | — | CN | disclosed |
| EP-1633691-A1 | METHOD FOR PRODUCING 2,2'-DIHYDROXY-BIPHENYLS | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005042454-A1 | METHOD FOR THE PRODUCTION OF 2,2'-DIHYDROXYBIPHENYLS | BASF AKTIENGESELLSCHAFT (DE) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004108642-A1 | METHOD FOR PRODUCING 2,2'-DIHYDROXY-BIPHENYLS | BASF AKTIENGESELLSCHAFT (DE) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004069779-A1 | METHOD FOR PRODUCING 2,2'-DIHYDROXYBIPHENYLS | BASF AKTIENGESELLSCHAFT (DE) | 2004-08-19 | — | — | WO | disclosed |
| US-4368299-A | MOLDING MATERIALS, LAMINATION, PAINTS, ADHESIVES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091050-A1 | Process For Producing Phosphonitrilic Acid Ester | PHOSPHO1, GNPAT, SELENOI | ALDH1A1 1163/4885GABRA1 2466/4885GABRB2 2320/4885 |
| US-20070129578-A1 | Method for the production of 2,2'-dihydroxybiphenyls | HAO2, DAO, DDO | ALDH1A1 1084/4885GABRA1 1782/4885GABRB2 1341/4885 |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | ALDH1A1 1694/4885GABRA1 3586/4885GABRB2 3344/4885 |
| US-20140336106-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | ALDH1A1 1694/4885GABRA1 3586/4885GABRB2 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.